#Mechanism | #Regenerative | #Vascular

BPC-157 (Body Protection Compound-157)

Unlike many short peptides that rapidly degrade in biological environments, BPC-157 demonstrated unusual stability in gastric conditions. This property led to expanded investigation into its systemic effects in animal models, particularly its role in soft tissue repair, vascular signaling, and nitric oxide (NO) pathway modulation.

Peptide Name

Type

Synthetic Peptide Fragment

Sequence Length

15 Amino Acids

CAS Number

137525-51-0

Primary Research Focus

Tissue Repair & Angiogenesis

Research Status

Preclinical / Experimental

Molecular Formula:

C₆₂H₉₈N₁₆O₂₂

Molecular Weight

~1419.5 Da

Amino Acid Sequence

Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val

Research Context

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It was identified during investigations into endogenous cytoprotective mechanisms responsible for maintaining gastric mucosal integrity. Unlike many short peptides that rapidly degrade in biological environments, BPC-157 demonstrated unusual stability in gastric conditions. This property led to expanded investigation into its systemic effects in animal models, particularly its role in soft tissue repair, vascular signaling, and nitric oxide (NO) pathway modulation.

Store powder at +4°C (short term) or -20°C (long term). Keep desiccated.

For laboratory research use only. Reconstitute using sterile bacteriostatic water consistent with established laboratory research protocols. Preparation should be performed under aseptic conditions. Reconstituted material is not intended for long-term storage.

Amino Acid Sequence

Origin & Development

BPC-157 was first synthesized in the early 1990s at the University of Zagreb, Croatia. The original research objective was to isolate a stable peptide fragment capable of reproducing the cytoprotective effects of the larger gastric BPC protein.
Subsequent studies observed unexpected effects in musculoskeletal and vascular repair models, prompting broader investigation into angiogenesis, connective tissue healing, and endothelial signaling pathways.

Proposed Biological Activities (Preclinical)

Tissue Repair & Wound Models

Rodent studies have reported accelerated closure of surgical wounds and enhanced granulation tissue formation. These effects are hypothesized to involve fibroblast migration and modulation of growth factor signaling within injured tissue.

Angiogenesis & Vascular Research

BPC-157 is frequently cited for its potential to promote angiogenesis in ischemic tissue models. Evidence suggests involvement of the VEGFR2 signaling axis, contributing to improved perfusion and endothelial stability.

Tendon, Ligament & Connective Tissue

In transected rat Achilles tendon models, BPC-157 administration was associated with increased load-to-failure strength and improved collagen fiber organization compared to controls.

Antioxidant & Anti-Inflammatory Effects

Preclinical studies indicate BPC-157 may counteract NSAID-induced gastrointestinal damage, potentially through preservation of mucosal integrity and reduction of oxidative stress markers.

Central Nervous System (Exploratory)

Exploratory research has examined BPC-157 in models of traumatic brain injury (TBI), where neuroprotective effects were observed. These findings remain preliminary, and the precise molecular pathways involved have not been fully characterized.

Environmental & Non-Medical Research

Non-clinical investigations have explored the peptide’s chemical stability and its capacity to interact with specific environmental toxins in biological systems, suggesting potential utility beyond traditional biomedical models.

Research Limitations

Lack of Human Trials: The majority of available data originates from rodent models. Controlled human clinical trial data is minimal or unpublished.
Mechanistic Ambiguity: While biological effects are observed, definitive receptor targets remain poorly defined relative to well-mapped peptides (e.g., insulin, GLP-1).
Bioavailability Debate: Although stable in gastric environments, systemic absorption kinetics in humans remain unresolved, particularly when comparing oral versus parenteral models.

Scientific References

Jelovac, N., et al. (1998). Pentadecapeptide BPC-157 attenuates disturbances after acute pancreatitis in rats. Pancreas, 16(2), 209-218.
Sikirić, P., et al. (1997). Pentadecapeptide BPC-157 heals vitamin D₃-induced hypercalcemia in rats. Life Sciences, 60(24), 2133-2146.
Huang, T., et al. (2015). The promoting effect of pentadecapeptide BPC-157 on tendon healing involves cell migration and survival. Journal of Applied Physiology, 118(8), 961-970.
Chang, C. H., et al. (2011). Journal of Applied Physiology, 110(3), 774-780.
Hsieh, M. J., et al. (2017). Biomedicine & Pharmacotherapy, 88, 394-401.
Sikirić, P., et al. (2018). Journal of Physiology and Pharmacology, 69(2), 159-176.
Tudor, M., et al. (2010). Regulatory Peptides, 160(1-3), 26-32.

The compound listed below is referenced in research contexts related to the mechanisms discussed in this article.

The compound BPC-157 discussed on this page is a chemical standard intended strictly for in-vitro and laboratory research applications (e.g., receptor binding assays, cell culture studies). It is not a drug, dietary supplement, or food additive. It is not intended for human consumption, injection, or therapeutic use. All handling must be performed by qualified professionals in a laboratory setting.

BPC-157 (Body Protection Compound-157)

Peptide Name

Type

Sequence Length

CAS Number

Primary Research Focus

Research Status

Molecular Formula:

Molecular Weight

Amino Acid Sequence

Research Context

Amino Acid Sequence

Age Verification Required

GLP2-T

Thymosin Alpha-1 (TA1)

Tesamorelin

TB-500

SS-31

Semax

Selank

GLP3-R

PT-141